Claire Mazumdar Sells 36,766 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 36,766 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $19.17, for a total value of $704,804.22. Following the transaction, the chief executive officer owned 339,392 shares of the company’s stock, valued at $6,506,144.64. This represents a 9.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Claire Mazumdar also recently made the following trade(s):

• On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.75, for a total transaction of $71,568.75.
• On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.73, for a total transaction of $49,278.63.
• On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.74, for a total transaction of $33,469.64.

Bicara Therapeutics Stock Performance

Shares of NASDAQ:BCAX traded down $0.16 on Wednesday, reaching $19.90. The company’s stock had a trading volume of 390,018 shares, compared to its average volume of 511,073. Bicara Therapeutics Inc. has a 52-week low of $7.80 and a 52-week high of $20.25. The company has a market cap of $1.09 billion, a P/E ratio of -8.88 and a beta of -0.78. The company has a 50-day simple moving average of $16.61 and a 200 day simple moving average of $15.93.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. UBS Group reissued a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. HC Wainwright reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Wedbush reissued an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, January 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, January 9th. Finally, Wells Fargo & Company raised their price target on Bicara Therapeutics from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Bicara Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.33.

Institutional Trading of Bicara Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc boosted its position in shares of Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares during the period. Ameritas Investment Partners Inc. lifted its stake in shares of Bicara Therapeutics by 73.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after acquiring an additional 1,474 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after acquiring an additional 3,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in Bicara Therapeutics during the 4th quarter valued at $45,000. Finally, Larson Financial Group LLC grew its position in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after acquiring an additional 3,595 shares during the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.